XOLAIR®
XOLAIR® (Omalizumab) is an immunosuppressive drug used to treat moderate to severe persistent allergic asthma not controlled by inhaled corticosteroids and chronic idiopathic urticaria not controlled by H1 antihistamines.
XOLAIR® is manufactured by Genentech/Novartis.
Administration and Dosage:
Administration of XOLAIR is a subcutaneous injection every 2 or 4 weeks.
Common Side Effects:
The more common side effects of XOLAIR® include cancer, inflammation of blood vessels, parasite infection, heart and circulation problems, and fever, muscle aches, and rash.
Indication:
XOLAIR® is indicated to treat:
Moderate to Severe Persistent Allergic Asthma
Chronic Idiopathic Urticaria.
More information:
Please read the full Prescribing Information and Medication Guide for XOLAIR® and discuss any questions you have with your doctor.
Contact Us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!
Check our Privacy Practice